Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

2.

How artificial intelligence could significantly improve the prognosis for cancer patients.

3.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

4.

High numbers of rural patients cross state lines for cancer care

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot